Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2004-02-02
2008-03-04
Kemmerer, Elizabeth C. (Department: 1649)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387300, C530S387100
Reexamination Certificate
active
07339035
ABSTRACT:
It is intended to provide an antibody efficacious in diagnosing, preventing or treating Alzheimer's disease, DNA encoding the antibody, a method of screening a drug and drugs. The amino acid sequence and the gene sequence of the variable region of an antibody, which specifically recognizes a GM1 ganglioside-bound amyloid β-protein occurring in the early stage of β-amyloid fibril formation, are determined. Based on the data of the amino acid sequence and the gene sequence thus obtained, an antibody is designed.
REFERENCES:
patent: 5530101 (1996-06-01), Queen et al.
patent: 620 276 (1990-12-01), None
patent: WO 90/07861 (1990-07-01), None
Paul WE. Fundamental Immunology, 1993, Raven Press, New York, pp. 292-295.
Radikoff S et al. Single amino acid substitution altering antigen-binding specificity. Proc Natl Acad Sci USA, 1982; 79: 1979-1983.
Webber KO et al. Preparation and characterization of a disulfide-stabilized Fv fragment of the anti-Tac antibody: comparison with its single-chain analog. Mol Immunol, 1995; 32(4): 249-258.
Yanagisawa et al., “GM1 Ganglioside-Bound Amyloid β-Protein (Aβ): A Possible Form of Preamyloid in Alzheimer's Disease”, Nature Medicine, vol. 1, No. 10, pp. 1062-1066, 1995.
Yanagisawa et al., “GM1 Ganglioside-Bound Amyloid β-Protein in Alzheimer's Disease Brain”, Neurobiology of Aging, vol. 19, No. 1S, pp. S65-S67, 1998.
Yanagisawa et al., “Amyloid β-Protein (Aβ) Associated with Lipid Molecules: Immunoreactivity Distinct From that of Soluble Aβ”, FEBS Letters 420 (1997) 43-46.
McLaurin et al., “Membrane Disruption by Alzheimer β-Amyloid Peptides Mediated . . . ”, Journal of Biological Chemistry, vol. 271, No. 43, pp. 26482-26489, 1996.
Choo-Smith et al., “The Interaction between Alzheimer Amyloid β(1-40) Peptide and Ganglioside GM1-Containing Membranes”, FEBS Letters 402 (1997) 95-98.
Choo-Smith et al., “Acceleration of Amyloid Fibril Formation by Specific Binding of Aβ-(1-40) Peptide . . . ”, Journal of Biological Chemistry, vol. 272, No. 37, pp. 22987-22990, 1997.
Matsuzaki et al., “Interactions of Amyloid β-Peptide (1-40) with Ganglioside-Containing Membranes”, Biochemistry 1999, 38, 4137-4142.
Koppaka et al., “Accelerated Accumulation of Amyloid β Proteins on Oxidatively Damaged Lipid Membranes”, Biochemistry 2000, 39, 10011-10016.
Kakio et al., “Cholesterol-dependent Formation of GM1 Ganglioside-Bound Amyloid β-Protein, an Endogenous . . . ”, Journal of Biological Chemistry, vol. 276, No. 27, pp. 24985-24990, 2001.
Igbavboa et al., “Increasing Age Alters Transbilayer Fluidity and Cholesterol Asymmetry in Synaptic . . . ”, J. Neurochem. 66, 1717-1725 (1996).
Igbavboa et al., “Transbilayer Distribution of Cholesterol Is Modified in Brain Synaptic Plasma Membranes . . . ”, J. Neurochem. 69, 1661-1667 (1997).
R.G. Parton, “Ultrastructural Localization of Gangliosides; GM1Is Concentrated in Caveolae”, Journal of Histochemistry and Cytochemistry, vol. 42, No. 2, pp. 155-166, 1994.
Simons et al., “Functional Rafts in Cell Membranes”, Nature vol. 387, pp. 569-572, 1997.
Lee et al., “A Detergent-Insoluble Membrane Compartment Contains Aβ in Vivo”, Nature Medicine, vol. 4, No. 6, pp. 730-734, 1998.
Morishima-Kawashima et al., “The Presence of Amyloid β-Protein in the Detergent-Insoluble Membrane . . . ”, Biochemistry, vol. 37, No. 44, pp. 15247-15253, 1998.
Sawamura et al., “Mutant Presenilin 2 Transgenic Mice . . . ”, Journal of Biological Chemistry, vol. 275, No. 36, pp. 27901-27908, 2000.
Kim, et al., “Production and Characterization of Monoclonal Antibodies Reactive to Synthetic Cerebrovascular . . . ”, Neuroscience Research Communications vol. 2, No. 3, pp. 121-130, 1988.
Jones et al., “Replacing the Complementarity-Determining Regions in a Human Antibody with Those From a Mouse”, Nature vol. 321, No. 6069, pp. 522-525, 1986.
Yanagisawa et al., Internal Medicine, vol. 77, No. 5, pp. 797-803, 1996 (relates to the background of the invention).
Yanagisawa et al., Journal of Clinical and Experimental Medicine, Igaku No Ayumi, vol. 189, No. 1, pp. 3-8, 1999 (relates to the background of the invention).
Hayashi et al; “A Seed for Alzheimer Amyloid in the Brain”; The Journal of Neuroscience, May 19, 2004—24(20): pp. 4894-4902.
Supplementary European Search Report dated Nov. 18, 2004.
European Patent Office Action in counterpart application EP 02 755 765.1, dated Jul. 22, 2005.
Shibata Masao
Yanagisawa Katsuhiko
Ballard Kimberly A.
Edwards Angell Palmer & & Dodge LLP
Japan as Represented by the Director of Chubu National Hospital
Kemmerer Elizabeth C.
Medical & Biological Laboratories Co. Ltd.
LandOfFree
Antibody recognizing GM1 ganglioside-bound amyloid... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibody recognizing GM1 ganglioside-bound amyloid..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibody recognizing GM1 ganglioside-bound amyloid... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3968607